A pharmacokinetics (PK) bioequivalence trial of proposed trastuzumab biosimilar, Myl-1401O (A) vs EU-Herceptin (B) and US-Herceptin (C). (February 2017) - Waller, C.; Vutikullird, A.; Lawrence, T.; Shaw, A.; Liu, M.S.; Baczkowski, M.; Sharma, R.; Barve, A.; Pennella, E.